Revolution Medicines Q2 2024 GAAP EPS $(0.81) Misses $(0.77) Estimate
Portfolio Pulse from Benzinga Newsdesk
Revolution Medicines (NASDAQ:RVMD) reported a Q2 2024 GAAP EPS of $(0.81), missing the analyst consensus estimate of $(0.77) by 5.19%. This represents an 11.96% improvement over the $(0.92) loss per share from the same period last year.
August 07, 2024 | 9:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Revolution Medicines reported a Q2 2024 GAAP EPS of $(0.81), missing the analyst estimate of $(0.77) by 5.19%. However, the loss per share improved by 11.96% compared to the same period last year.
The miss on the EPS estimate is likely to have a negative short-term impact on RVMD's stock price. However, the year-over-year improvement in losses may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100